Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

NCT06121765 | Unknown

• 1 other identifier: Metabolic alteration in CML
• Study Type: observational
• Target: 45
• Locations: 0 countries
• Sites: N/A

Brief Summary

Metabolic alternation and clinicohematological characteristic in chronic phase CML in patient treated with TKI

Conditions

CML, Chronic Phase

Outcome Measures

Primary Outcomes (1)

• Evaluation of BMI in patient diagnosed CMLm b. S Evaluat BMI in patient newly diagnosed CMLm , Triglyceride-to-High Density Lipoprotein Cholesterol Ratio b. S

  Evaluation of weight in kg and height in meter will be combined to measure BMI in (kg/m2)

  Base line

Interventions

Tyrosine kinase inhibitor OTHER

Follow up base metabolic index,lipid profile, HbA1c, thyroid function in CML patients treated with TKI

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Chronic myeloid leukemia (CML), a clonal hematopoietic stem cell malignancy, is characterized by unique translocation leading to the formation of the Philadelphia chromo- some.1 Because of the specific genotype knowledge, tyrosine kinase inhibitors have been used in CML and have significantly improved the prognosis of patients with CML, especially n high-income countries like the United States.2,3 Notably, the 5-year survival rates increased from 40% to 90%. So, CML is increasingly seen as a chronic instead of a potentially fatal disease.

You may qualify if:

• Patient newly diagnosed with CML and received TKI

You may not qualify if:

• patient previously diagnosed CML and started treatment or in post treatment follow up

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Leukemia, Myeloid, Chronic-Phase

Interventions

Tyrosine Kinase Inhibitors

Condition Hierarchy (Ancestors)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses

Central Study Contacts

Noha Rabea, Resident doctor

CONTACT

01126858606; nohahamzawy4@gmail.com

Mohamed Ramdan, Professor

CONTACT

dr.muhamadramadan@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: October 29, 2023
• First Posted: November 8, 2023
• Study Start: November 1, 2023
• Primary Completion: October 30, 2025
• Study Completion: November 30, 2025
• Last Updated: November 8, 2023

Record last verified: 2023-11